These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

338 related items for PubMed ID: 30539362

  • 1. Lanadelumab for the Prophylactic Treatment of Hereditary Angioedema with C1 Inhibitor Deficiency: A Review of Preclinical and Phase I Studies.
    Busse PJ, Farkas H, Banerji A, Lumry WR, Longhurst HJ, Sexton DJ, Riedl MA.
    BioDrugs; 2019 Feb; 33(1):33-43. PubMed ID: 30539362
    [Abstract] [Full Text] [Related]

  • 2. Lanadelumab for the prevention of attacks in hereditary angioedema.
    Valerieva A, Senter R, Wu MA, Zanichelli A, Cicardi M.
    Expert Rev Clin Immunol; 2019 Dec; 15(12):1239-1248. PubMed ID: 31721602
    [Abstract] [Full Text] [Related]

  • 3. Interventions for the long-term prevention of hereditary angioedema attacks.
    Beard N, Frese M, Smertina E, Mere P, Katelaris C, Mills K.
    Cochrane Database Syst Rev; 2022 Nov 03; 11(11):CD013403. PubMed ID: 36326435
    [Abstract] [Full Text] [Related]

  • 4. Lanadelumab for the treatment of hereditary angioedema.
    Wu MA.
    Expert Opin Biol Ther; 2019 Dec 03; 19(12):1233-1245. PubMed ID: 31657963
    [Abstract] [Full Text] [Related]

  • 5. Indirect Comparison of Lanadelumab and Intravenous C1-INH Using Data from the HELP and CHANGE Studies: Bayesian and Frequentist Analyses.
    Mendivil J, Malmenäs M, Haeussler K, Hunger M, Jain G, Devercelli G.
    Drugs R D; 2021 Mar 03; 21(1):113-121. PubMed ID: 33646565
    [Abstract] [Full Text] [Related]

  • 6. An open-label study to evaluate the long-term safety and efficacy of lanadelumab for prevention of attacks in hereditary angioedema: design of the HELP study extension.
    Riedl MA, Bernstein JA, Craig T, Banerji A, Magerl M, Cicardi M, Longhurst HJ, Shennak MM, Yang WH, Schranz J, Baptista J, Busse PJ.
    Clin Transl Allergy; 2017 Mar 03; 7():36. PubMed ID: 29043014
    [Abstract] [Full Text] [Related]

  • 7. Lanadelumab to treat hereditary angioedema.
    Wedi B.
    Drugs Today (Barc); 2019 Jul 03; 55(7):439-448. PubMed ID: 31347612
    [Abstract] [Full Text] [Related]

  • 8. Lanadelumab: A Review in Hereditary Angioedema.
    Syed YY.
    Drugs; 2019 Nov 03; 79(16):1777-1784. PubMed ID: 31560114
    [Abstract] [Full Text] [Related]

  • 9. Pharmacokinetics, Pharmacodynamics, and Exposure-Response of Lanadelumab for Hereditary Angioedema.
    Wang Y, Marier JF, Kassir N, Chang C, Martin P.
    Clin Transl Sci; 2020 Nov 03; 13(6):1208-1216. PubMed ID: 32407574
    [Abstract] [Full Text] [Related]

  • 10. Therapeutic monoclonal antibodies with a focus on hereditary angioedema.
    Zuraw BL, Maurer M, Sexton DJ, Cicardi M.
    Allergol Int; 2023 Jan 03; 72(1):54-62. PubMed ID: 35787344
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Inhibiting Plasma Kallikrein for Hereditary Angioedema Prophylaxis.
    Banerji A, Busse P, Shennak M, Lumry W, Davis-Lorton M, Wedner HJ, Jacobs J, Baker J, Bernstein JA, Lockey R, Li HH, Craig T, Cicardi M, Riedl M, Al-Ghazawi A, Soo C, Iarrobino R, Sexton DJ, TenHoor C, Kenniston JA, Faucette R, Still JG, Kushner H, Mensah R, Stevens C, Biedenkapp JC, Chyung Y, Adelman B.
    N Engl J Med; 2017 Feb 23; 376(8):717-728. PubMed ID: 28225674
    [Abstract] [Full Text] [Related]

  • 13. Recombinant human C1 esterase inhibitor in the management of hereditary angioedema.
    Riedl M.
    Clin Drug Investig; 2015 Jul 23; 35(7):407-17. PubMed ID: 26091744
    [Abstract] [Full Text] [Related]

  • 14. A review of kallikrein inhibitor lanadelumab in hereditary angioedema.
    Hwang G, Johri A, Ng S, Craig T.
    Immunotherapy; 2019 Aug 23; 11(11):937-944. PubMed ID: 31234673
    [Abstract] [Full Text] [Related]

  • 15. Patient-level indirect treatment comparison of lanadelumab versus pdC1-INH i.v. in hereditary angioedema patients: PATCH study.
    Magerl M, Schiffhorst G, Fanter L, Müller G, Hirche C, Berkemeier F, Aygören E.
    Allergy; 2024 Jan 23; 79(1):215-224. PubMed ID: 37641968
    [Abstract] [Full Text] [Related]

  • 16. Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial.
    Craig T, Magerl M, Levy DS, Reshef A, Lumry WR, Martinez-Saguer I, Jacobs JS, Yang WH, Ritchie B, Aygören-Pürsün E, Keith PK, Busse P, Feuersenger H, Pawaskar D, Jacobs I, Pragst I, Doyle MK.
    Lancet; 2022 Mar 05; 399(10328):945-955. PubMed ID: 35219377
    [Abstract] [Full Text] [Related]

  • 17. Lanadelumab Injection Treatment For The Prevention Of Hereditary Angioedema (HAE): Design, Development And Place In Therapy.
    Bova M, Valerieva A, Wu MA, Senter R, Perego F.
    Drug Des Devel Ther; 2019 Mar 05; 13():3635-3646. PubMed ID: 31695331
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Treatment of Hereditary Angioedema.
    Caballero T.
    J Investig Allergol Clin Immunol; 2021 Feb 05; 31(1):1-16. PubMed ID: 33602658
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.